Skip to main content
PCR logo

Simplify VettaFi Private Credit Strategy ETF (PCR) Fund Overview

Educational signal · not a buy or sell recommendation · How to read this

$18.13 +$0.0032 (+0.02%)
Vol: 5|

Beta 2.26: the stock has moved about 126% more than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Simplify VettaFi Private Credit Strategy ETF (PCR) trades at $18.13. Simplify VettaFi Private Credit Strategy ETF (PCR) is focused on generating income and capital appreciation through investments in private credit strategies and credit hedge derivatives. Sector: Financials.

Price as of · Last analyzed: Mar 17, 2026
Simplify VettaFi Private Credit Strategy ETF (PCR) is focused on generating income and capital appreciation through investments in private credit strategies and credit hedge derivatives. The ETF primarily targets business development companies and publicly-traded closed-end funds in the private credit sector.

Analyst Coverage for PCR: PCR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

▶ Watch the PCR film Every key number, told as a short cinematic story — just press play. ~2 min

Simplify VettaFi Private Credit Strategy ETF (PCR) Financial Services Profile

IPO Year2025

Simplify VettaFi Private Credit Strategy ETF (PCR) leverages innovative private credit strategies and credit hedging to pursue income and capital appreciation, positioning itself uniquely within the asset management sector.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 17, 2026

What Is the Investment Thesis for PCR?

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

The investment thesis for Simplify VettaFi Private Credit Strategy ETF (PCR) centers on its innovative approach to private credit and credit hedging. By investing in BDCs and CEFs, PCR taps into a market segment that has experienced robust growth, driven by increasing demand for alternative financing solutions. The private credit market is projected to grow significantly, with estimates suggesting a compound annual growth rate (CAGR) of around 10% over the next five years. Additionally, the proprietary hedging strategy may provide downside protection during market fluctuations, enhancing the ETF's risk-adjusted returns. However, investors may want to evaluate the lack of dividend yield as a potential drawback, focusing instead on capital appreciation as the primary value driver. Overall, PCR's unique positioning within the asset management sector, combined with its strategic investment approach, presents a compelling case for growth in the coming years.

Based on FMP financials and quantitative analysis

PCR Key Highlights

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

Market Cap: $0.00B, indicating a focus on capital appreciation rather than income generation.

  • Beta: 2.26, suggesting higher volatility compared to the broader market.
  • No dividend yield, emphasizing a strategy focused on capital growth.
  • Invests in BDCs and CEFs, tapping into the growing private credit market.
  • Utilizes a proprietary credit hedge strategy to manage risk.

Who Are PCR's Competitors?

What Are PCR's Key Strengths?

Innovative investment strategy focusing on private credit.

  • Proprietary hedging strategy enhances risk management.
  • Strong growth potential in the private credit market.

What Are PCR's Weaknesses?

No dividend yield may deter income-focused investors.

  • Higher volatility indicated by a beta of 2.26.
  • Limited brand recognition compared to larger asset managers.

What Are the Key Risks for PCR?

Market volatility could adversely affect the ETF's performance.

  • Regulatory changes may impact the operational landscape for private credit investments.
  • Competition from other asset managers may dilute market share.

What Threats Does PCR Face?

  • Market volatility could impact performance and investor sentiment.
  • Competition from other asset managers focusing on private credit.
  • Economic downturns may reduce demand for private credit solutions.

What Are PCR's Competitive Advantages?

  • Proprietary credit hedge derivatives strategy provides a competitive edge in risk management.
  • Focus on BDCs and CEFs allows for specialized investment in a growing sector.
  • Strong positioning within the private credit market, which is less saturated than traditional markets.
  • Adaptability to regulatory changes enhances long-term viability and compliance.
  • Innovative approach to income generation and capital appreciation differentiates PCR from traditional ETFs.

What Does PCR Do?

The Simplify VettaFi Private Credit Strategy ETF (PCR) was established to capitalize on the growing demand for private credit investment opportunities. Its founding vision was to create a financial product that not only seeks income but also capital appreciation through a diversified approach. The ETF primarily invests in business development companies (BDCs) and publicly-traded closed-end funds (CEFs) that focus on the private credit sector, which has seen significant growth in recent years as traditional lending avenues have tightened. The investment strategy is complemented by a proprietary credit hedge derivatives strategy, which employs a long/short hedge based on total return swaps of both 'quality' and 'junk' equities. This dual approach allows PCR to navigate market volatility while seeking to enhance returns. The ETF is designed for investors looking for exposure to the private credit market, which is characterized by higher yields compared to traditional fixed-income investments. With no dividend yield currently, PCR emphasizes capital growth through its strategic investments. The ETF's market position is bolstered by the increasing interest in alternative investment strategies, particularly in a low-interest-rate environment. As the private credit market continues to evolve, PCR aims to adapt and expand its investment strategies to maintain a competitive edge.

What Products and Services Does PCR Offer?

  • Invests in business development companies (BDCs) that focus on private credit.
  • Allocates capital to publicly-traded closed-end funds (CEFs) in the private credit sector.
  • Employs a proprietary credit hedge derivatives strategy to manage risk.
  • Seeks income and capital appreciation through diversified investment strategies.
  • Focuses on both 'quality' and 'junk' equities for hedging purposes.
  • Targets higher yields compared to traditional fixed-income investments.

How Does PCR Make Money?

  • Generates returns through investments in BDCs and CEFs focused on private credit.
  • Utilizes a proprietary hedging strategy to mitigate risk and enhance returns.
  • Seeks to capitalize on the growing demand for alternative financing solutions.
  • Focuses on capital appreciation rather than income generation, given the lack of dividends.
  • Targets investors looking for exposure to the private credit market.

What Industry Does PCR Operate In?

The asset management industry, particularly in the private credit sector, has experienced significant growth as investors seek higher yields in a low-interest-rate environment. The increasing prevalence of business development companies and closed-end funds has provided new avenues for capital allocation. As traditional banks tighten lending standards, private credit strategies are becoming more attractive to institutional and retail investors alike. The market for private credit is expected to expand, with estimates suggesting a CAGR of approximately 10% over the next several years, indicating strong demand for products like PCR that focus on this niche.

Who Are PCR's Key Customers?

  • Institutional investors seeking alternative investment opportunities.
  • Retail investors looking for exposure to private credit markets.
  • Financial advisors and wealth managers recommending diversified portfolios.
  • High-net-worth individuals interested in capital appreciation strategies.
  • Pension funds and endowments searching for yield enhancement.
Model self-rating on this text: 65% (not a measure of the evidence) Updated: Mar 17, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
  • ● This is an etf, not an operating company

PCR Financials

Bull Case vs Bear Case

Bull Case

  • Innovative investment strategy focusing on private credit.
  • Proprietary hedging strategy enhances risk management.
  • Strong growth potential in the private credit market.
  • Upcoming: Increased investor interest in alternative investments as traditional markets fluctuate.

Bear Case

  • No dividend yield may deter income-focused investors.
  • Higher volatility indicated by a beta of 2.26.
  • Limited brand recognition compared to larger asset managers.
  • Potential: Market volatility could adversely affect the ETF's performance.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

PCR Latest News

PCR Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PCR.

Price Targets

Wall Street price target analysis for PCR.

PCR MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PCR; grades run from A+ (80-100) to F (below 30).

Simplify VettaFi Private Credit Strategy ETF Financials Stock: Key Questions Answered

What do analysts say about PCR stock?

Analysts generally view PCR as a unique investment vehicle within the private credit space, emphasizing its innovative approach and potential for capital appreciation.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

MoonshotScore is not published for this security.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Data is based on available information as of March 2026.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis